Chemotherapeutic Assay Selects Effective Treatments for Ovarian Cancer
At 6 months, the arm receiving chemotherapy selected by ChemoID had an ORR of 55%, compared with 5% in the physician choice arm. A chemotherapeutic assay (ChemoID) designed to to select targeted treatments for patients with platinum-resistant ovarian cancer, based on the cytotoxicity profile of patients’ cancer stem cells, significantly improved objective response rates (ORRs), … Read more